Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $13,132.35 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $3.15, for a total transaction of $13,132.35. Following the completion of the transaction, the insider now directly owns 134,921 shares in the company, valued at approximately $425,001.15. This represents a 3.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $3.49, for a total value of $12,836.22.

Amylyx Pharmaceuticals Stock Up 4.6 %

Shares of AMLX traded up $0.14 during trading on Wednesday, reaching $3.20. The company’s stock had a trading volume of 684,184 shares, compared to its average volume of 1,827,482. The company has a market cap of $219.35 million, a price-to-earnings ratio of -0.84 and a beta of -0.54. The company has a fifty day moving average of $3.64 and a two-hundred day moving average of $3.82. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95.

Analyst Upgrades and Downgrades

AMLX has been the subject of several analyst reports. Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Finally, Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.33.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its position in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after purchasing an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. Alpine Global Management LLC acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $45,000. RPO LLC acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $46,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after buying an additional 5,104 shares during the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.